Immune disorders in hemodialysis patients

Sharif, M.R. and Chitsazian, Z. and Moosavian, M. and Raygan, F. and Nikoueinejad, H. and Sharif, A. and Einollahi, B. (2015) Immune disorders in hemodialysis patients. Iranian Journal of Kidney Diseases, 9 (2). pp. 84-96.

Full text not available from this repository.
Official URL:


Immunologically, end-stage renal disease is associated with some disorders in both innate and adaptive immune system in such a form that there is a coexistence of both immune activation and immune suppression. Although these disorders are complex yet thoroughly unknown, there is a close relationship between the progressively defective immune system and side effects as well as mortality causes, including cardiovascular problems, infections, and malignancies. From the other viewpoint, chronic inflammation as a major determinant of �dialysis syndrome� is considered as the main factor of morbidity and mortality in dialysis patients. Such inflammation is generally arisen from immune system response to uremia and individual�s repetitive contact with dialysis instruments, and in the long-term, it leads to premature aging via intensifying tissue degeneration. Therefore, the immune system is known as one of the most important therapeutic targets to reduce morbidity and mortality in uremic and dialysis patients. This review addresses different aspects as well as mechanisms of immune system dysfunction and possible therapeutics in dialysis patients. © 2015, Iranian Society of Nephrology. All rights reserved.

Item Type: Article
Additional Information: cited By 6
Uncontrolled Keywords: C reactive protein; CD11b antigen; CD18 antigen; CD59 antigen; chemokine receptor CXCR4; complement component C3a; complement component C5a; cytochrome c; endothelial leukocyte adhesion molecule 1; endothelin 1; hepcidin; immunoglobulin enhancer binding protein; indoleamine 2, 3 dioxygenase; inducible nitric oxide synthase; interleukin 10; interleukin 12; interleukin 6; interleukin 8; natural killer cell receptor NKG2D; pentraxin 3; procalcitonin; reactive nitrogen species; reactive oxygen metabolite; stromal cell derived factor 1; toll like receptor 2; tumor necrosis factor alpha; unclassified drug; unindexed drug; uremic toxin; urokinase receptor; vasculotropin, apoptosis; Article; B lymphocyte; cell proliferation; chlamydial pneumonia; complement activation; endothelial dysfunction; Helicobacter pylori; hemodialysis; Hepatitis C virus; human; immunocompetent cell; immunopathology; inflammation; innate immunity; intracellular space; kidney clearance; Kupffer cell; leukopenia; natural killer cell; T lymphocyte; thrombosis; adverse effects; complication; Immune System Diseases; Kidney Failure, Chronic; pathophysiology; procedures; prognosis; renal replacement therapy; treatment outcome; uremia, Humans; Immune System Diseases; Kidney Failure, Chronic; Prognosis; Renal Dialysis; Treatment Outcome; Uremia
Subjects: Medicine
Divisions: Faculty of Medicine > Clinical Sciences > Department of Pediatrics
Depositing User: editor . 2
Date Deposited: 07 Mar 2017 19:03
Last Modified: 12 Mar 2017 13:57

Actions (login required)

View Item View Item